AccessDX


AccessDx Laboratory is dedicated to providing clinical insights that improve patient outcomes through advanced laboratory diagnostics solutions, including COVID-19 testing, pharmacogenomic testing, cancer genomic testing, and infectious disease testing. The company is CLIA-certified, CAP-accredited, and NYSDOH-approved, serving thousands of healthcare providers nationwide with a commitment to clinical excellence, innovation, and health equity.

Industries

biotechnology
health-care

Nr. of Employees

large (251-1000)

AccessDX

Houston, Texas, United States, North America


Products

PGx targeted gene panel

A clinically selected panel of genes and variants to assess medication-related genetic risk across therapeutic areas with clinician-facing interpretive reports.

UTI diagnostic panel (molecular + culture + AST)

Combined molecular detection of common UTI pathogens and resistance markers with culture-based antibiotic sensitivity to support rapid and confirmatory clinical decisions.

Population health and medication risk management platform

Platform functionality for real-time medication monitoring, alerts, cohort analytics, and program analytics to support medication-safety initiatives at facility and network scale.


Services

Pharmacogenomics testing service and interpretive reporting

Targeted PGx panel testing with clinical interpretation to identify drug-gene interactions and support medication optimization.

Molecular infectious disease testing

PCR-based pathogen detection and reporting for infectious disease diagnosis and stewardship initiatives.

Combined molecular + culture UTI testing (molecular speed + culture confirmation)

Service combining rapid molecular detection of urinary pathogens and resistance markers with culture and AST to enable faster and confirmatory clinical decisions.

Clinical decision support and medication risk monitoring (EHR-integrated) service

Continuous drug-gene monitoring and pharmacogenomic risk alerts delivered into clinical workflows and EHRs to help identify and remediate medication risks.

Variant detection and genomic surveillance (investigational)

Investigational variant-detection services using sequencing to identify emergent pathogen variants from PCR-positive samples, offered as a surveillance capability.

Expertise Areas

  • Pharmacogenomics
  • Molecular infectious disease diagnostics
  • Hereditary cancer genomics
  • Clinical decision support and EHR integration
  • Show More (4)

Key Technologies

  • Polymerase chain reaction (PCR)
  • Next-generation sequencing (NGS)
  • Microbiology culture and antibiotic susceptibility testing (AST)
  • Bioinformatics for clinical reporting
  • Show More (4)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.